1. Home
  2. TAOP vs LNAI Comparison

TAOP vs LNAI Comparison

Compare TAOP & LNAI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

TAOP

Taoping Inc.

HOLD

Current Price

$1.30

Market Cap

13.2M

Sector

Technology

ML Signal

HOLD

Logo Lunai Bioworks Inc.

LNAI

Lunai Bioworks Inc.

N/A

Current Price

$0.41

Market Cap

11.9M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
TAOP
LNAI
Founded
1993
N/A
Country
China
United States
Employees
N/A
29
Industry
Computer Software: Prepackaged Software
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
13.2M
11.9M
IPO Year
2012
N/A

Fundamental Metrics

Financial Performance
Metric
TAOP
LNAI
Price
$1.30
$0.41
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
30.0K
31.9M
Earning Date
04-28-2026
05-14-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.14
$0.15
52 Week High
$8.78
$1.66

Technical Indicators

Market Signals
Indicator
TAOP
LNAI
Relative Strength Index (RSI) 44.61 47.87
Support Level $1.23 $0.35
Resistance Level $1.59 $1.06
Average True Range (ATR) 0.22 0.12
MACD -0.01 0.02
Stochastic Oscillator 17.35 29.87

Price Performance

Historical Comparison
TAOP
LNAI

About TAOP Taoping Inc.

Taoping Inc is a provider of cloud-app technologies for smart city IoT platforms, digital advertising delivery, and other internet-based information distribution systems in China. Its operating segment includes Cloud-based Technology (CBT), Blockchain Technology (BT), and Traditional Information Technology (TIT). It generates maximum revenue from the CBT segment. CBT segment includes cloud-based products and services offered to customers in the private sector including new media, healthcare, education, and residential community management.

About LNAI Lunai Bioworks Inc.

Lunai Bioworks Inc is a biopharmaceutical company. Through its subsidiaries, it is mainly focused on developing allogeneic cell and gene therapies to promote stronger immune system responses, potentially for long-term or life-long cancer remission in some of the deadliest cancers. The group is engaged in the development of RENB-DC11 and RENB-DC20 (potential cell therapeutic vaccine candidates for different types of cancer); a proprietary AI platform that analyzes genetics to provide earlier and more accurate cancer diagnosis; and machine learning pipelines that harmonize and analyze complex, heterogeneous datasets to uncover clinically actionable insights. The group's reportable segments are: RENB, BioSymetrics, and RENC. Geographically, it operates in the United States and Netherlands.

Share on Social Networks: